Changmao Biochemical Engineering Company Limited, together with its subsidiaries, produces and sells organic acids for food additive, chemical, and pharmaceutical industries in Mainland China, Europe, the Asia Pacific, the United States, and internationally.
Flawless balance sheet and undervalued.
Share Price & News
How has Changmao Biochemical Engineering's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: 954's share price has been volatile over the past 3 months.
7 Day Return
1 Year Return
Return vs Industry: 954 exceeded the Hong Kong Chemicals industry which returned -31.4% over the past year.
Return vs Market: 954 underperformed the Hong Kong Market which returned -4% over the past year.
Price Volatility Vs. Market
How volatile is Changmao Biochemical Engineering's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 days ago | Simply Wall StThe Case For Changmao Biochemical Engineering Company Limited (HKG:954): Could It Be A Nice Addition To Your Dividend Portfolio?
2 weeks ago | Simply Wall StShould You Buy Changmao Biochemical Engineering Company Limited (HKG:954) For Its Upcoming Dividend In 4 Days?
3 weeks ago | Simply Wall StDo Insiders Own Lots Of Shares In Changmao Biochemical Engineering Company Limited (HKG:954)?
Is Changmao Biochemical Engineering undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: 954 (HK$0.66) is trading below our estimate of fair value (HK$11.24)
Significantly Below Fair Value: 954 is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: 954 is good value based on its PE Ratio (5.5x) compared to the Chemicals industry average (6.6x).
PE vs Market: 954 is good value based on its PE Ratio (5.5x) compared to the Hong Kong market (9.5x).
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate 954's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: 954 is good value based on its PB Ratio (0.5x) compared to the HK Chemicals industry average (0.7x).
How is Changmao Biochemical Engineering forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?
Forecasted Materials industry annual growth in earnings
In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as Changmao Biochemical Engineering has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.
This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.
- Examine whether Changmao Biochemical Engineering is trading at an attractive price based on how much it is expected to earn in the future, and relative to its industry peers and the wider market.
- Changmao Biochemical Engineering competitive advantages and company strategy can generally be found in its financial reports archived here.
- Explore growth companies in the Materials industry.
How has Changmao Biochemical Engineering performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: 954 has high quality earnings.
Growing Profit Margin: 954's current net profit margins (11.8%) are higher than last year (7.9%).
Past Earnings Growth Analysis
Earnings Trend: 954's earnings have grown by 9.2% per year over the past 5 years.
Accelerating Growth: 954's earnings growth over the past year (15.4%) exceeds its 5-year average (9.2% per year).
Earnings vs Industry: 954 earnings growth over the past year (15.4%) exceeded the Chemicals industry -9.9%.
Return on Equity
High ROE: 954's Return on Equity (8.7%) is considered low.
How is Changmao Biochemical Engineering's financial position?
Financial Position Analysis
Short Term Liabilities: 954's short term assets (CN¥310.7M) exceed its short term liabilities (CN¥73.1M).
Long Term Liabilities: 954's short term assets (CN¥310.7M) exceed its long term liabilities (CN¥2.3M).
Debt to Equity History and Analysis
Debt Level: 954's debt to equity ratio (3.1%) is considered satisfactory.
Reducing Debt: 954's debt to equity ratio has reduced from 16.7% to 3.1% over the past 5 years.
Debt Coverage: 954's debt is well covered by operating cash flow (577.2%).
Interest Coverage: 954's interest payments on its debt are well covered by EBIT (247.4x coverage).
What is Changmao Biochemical Engineering's current dividend yield, its reliability and sustainability?
Current Dividend Yield
Dividend Yield vs Market
Notable Dividend: 954's dividend (9.12%) is higher than the bottom 25% of dividend payers in the Hong Kong market (2.43%).
High Dividend: 954's dividend (9.12%) is in the top 25% of dividend payers in the Hong Kong market (7.03%)
Stability and Growth of Payments
Stable Dividend: 954 has been paying a dividend for less than 10 years and during this time payments have been volatile.
Growing Dividend: 954's dividend payments have increased, but the company has only paid a dividend for 9 years.
Current Payout to Shareholders
Dividend Coverage: With its reasonably low payout ratio (50%), 954's dividend payments are well covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: Insufficient data to determine if a dividend will be paid in 3 years and that it will be covered by earnings.
How experienced are the management team and are they aligned to shareholders interests?
Average board tenure
Chun Pan (49yo)
Mr. Chun Pan has been General Manager of Changmao Biochemical Engineering Company Limited since April 1, 2014 and also serves as its Chief Executive Officer. Mr. Pan served as Deputy General Manager of Cha ...
CEO Compensation Analysis
Compensation vs Market: Chun's total compensation ($USD173.94K) is about average for companies of similar size in the Hong Kong market ($USD228.98K).
Compensation vs Earnings: Chun's compensation has increased by more than 20% in the past year.
|Chairman & Compliance Officer||no data||CN¥1.85m||0.71% CN¥2.5m|
|CEO, GM & Executive Director||no data||CN¥1.23m||no data|
|Manager of Sales Department & Supervisor||4yrs||no data||no data|
|Non-Executive Director||no data||CN¥225.00k||0.0098% CN¥34.3k|
|Non-Executive Director||no data||CN¥225.00k||12.95% CN¥45.3m|
|Non-Executive Director||no data||CN¥225.00k||no data|
|Chairman of the Supervisory Board||no data||CN¥56.00k||no data|
|Independent Non-Executive Director||19yrs||CN¥60.00k||no data|
|Non-Executive Director||13yrs||CN¥225.00k||no data|
|Independent Non-Executive Director||15.75yrs||CN¥60.00k||no data|
Experienced Board: 954's board of directors are seasoned and experienced ( 14.4 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.
Changmao Biochemical Engineering Company Limited's company bio, employee growth, exchange listings and data sources
- Name: Changmao Biochemical Engineering Company Limited
- Ticker: 954
- Exchange: SEHK
- Founded: 1992
- Industry: Specialty Chemicals
- Sector: Materials
- Market Cap: HK$349.602m
- Shares outstanding: 529.70m
- Website: https://changmaobio.todayir.com
Number of Employees
- Changmao Biochemical Engineering Company Limited
- No. 1228 Chang Jiang Bei Road
- New North Zone
- Jiangsu Province
|Ticker||Exchange||Primary Security||Security Type||Country||Currency||Listed on|
|954||SEHK (The Stock Exchange of Hong Kong Ltd.)||Yes||Foreign Shares-Foreign Listed||HK||HKD||Jun 2002|
Changmao Biochemical Engineering Company Limited, together with its subsidiaries, produces and sells organic acids for food additive, chemical, and pharmaceutical industries in Mainland China, Europe, the Asia Pacific, the United States, and internationally. Its products include fumaric acid, maleic acid, L-malic acid, D-malic acid, DL-malic acid, L(+)-tartaric acid, D(-)-tartaric acid, DL-tartaric acid, L-aspartic acid, and aspartame used as food additives, pharmaceutical adjuvant, and active pharmaceutical ingredient, etc. The company is also involved in the research and development of medicine and nutraceutical products; production and sale of food additives; trading of organic acids; and property holding activities. Changmao Biochemical Engineering Company Limited was founded in 1992 and is headquartered in Changzhou, the People's Republic of China.
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2020/06/06 13:05|
|End of Day Share Price||2020/06/05 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.